Physician profile
Daniel Feldman
NPI 1720251317
$2,500.67
in general payments reported to CMS, 2019-2025
22 companies · $18.29 in 2025
The $18.29 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,029 · 2020: $562 · 2021: $803 · 2022: $88.49 · 2025: $18.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $834.44 | 2019-2022 | |
| Medtronic USA, INC. | $346.97 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $296.67 | 2019-2022 | |
| Redhill Biopharma INC. | $222.45 | 2020-2021 | |
| Allergan, INC. | $125.00 | 2021 | |
| Scilex Pharmaceuticals INC. | $111.00 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $90.59 | 2019-2020 | |
| Depuy Synthes Sales INC. | $76.10 | 2019-2020 | |
| Daiichi Sankyo INC. | $72.41 | 2019 | |
| Boston Scientific Corporation | $57.37 | 2020-2021 | |
| Horizon Therapeutics Plc | $41.67 | 2019-2021 | |
| Assertio Therapeutics, INC. | $33.81 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.84 | 2019 | |
| Pfizer INC. | $25.01 | 2019-2020 | |
| Si-Bone, INC. | $22.92 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Relievant Medsystems, INC. | $21.70 | 2021 | |
| Orthofix Medical, INC. | $18.29 | 2025 | Physio-Stim |
| Vertical Pharmaceuticals, LLC | $16.86 | 2019 | |
| Avanos Medical | $14.87 | 2019 | |
| Zyla Life Sciences, INC. | $14.30 | 2019 | |
| Shionogi INC | $13.82 | 2019 | |
| Ibsa Pharma INC. | $12.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.